The most serious adverse events noted in patients receiving dabrafenib include squamouscell carcinomas of the skin, tumor promotion in BRAF wild-type melanoma, serious febrile reactions,hyperglycemia, and uveitis/iritis. This evidence concerns the gene BRAF and neoplasm.